Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes

Metastatic urothelial carcinoma of the bladder, ureter, or renal pelvis is a highly aggressive disease with poor outcomes. Even with platinum-based chemotherapy, the median overall survival is 15 months and the 5-year survival is only 15%.

The role of metastasectomy in urothelial carcinoma is currently undefined.

To examine the use and outcomes of metastasectomy in older patients with urothelial carcinoma in a large population-based dataset.

We conducted a SEER-Medicare study, and from 70,648 urothelial carcinoma patients who met inclusion criteria, we identified 497 patients who had at least 1 metastasectomy during a median follow-up of 40 months.

The primary study endpoints were metastasectomy use, the length of stay for metastasectomy, complications, and overall survival following metastasectomy. Secondary outcomes included 30-day mortality and readmission rate following metastasectomy.

We identified 497 patients meeting inclusion criteria who had at least 1 metastasectomy during the study period including 24 patients who had more than 1 procedure resulting in a total of 523 metastasectomies. The median overall survival after the first metastasectomy was 19 months (95% CI: 15-23; interquartile range: 4-74). In this selected patient population, over a third of patients were alive at 3 years. In the 476 patients who had evaluable discharge dates, the median length of stay after metastasectomy was 7 days (IQR: 4-12), and 10% of patients had at least 1 complication within 30 days of discharge. Thirty-day mortality after metastasectomy was 10% (n = 53/523) and was largely driven by the mortality associated with resections of urothelial cancer brain metastases.

In well-selected patients with urothelial carcinoma with a reasonable life expectancy, resection of metastatic lesions is safe and is associated with long-term survival and potential cures.

Urologic oncology. 2017 Oct 04 [Epub ahead of print]

Bishoy M Faltas, Renee L Gennarelli, Elena Elkin, Daniel P Nguyen, Jim Hu, Scott T Tagawa

Division of Hematology and Medical Oncology, Weill-Cornell Medicine, New York, NY., Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY., Department of Urology, Weill-Cornell Medicine, New York, NY., Division of Hematology and Medical Oncology, Weill-Cornell Medicine, New York, NY; Department of Urology, Weill-Cornell Medicine, New York, NY. Electronic address: .


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.